

To the shareholders of Nordic Nanovector ASA

NOTICE OF ANNUAL GENERAL MEETING OF NORDIC NANOVECTOR ASA

Notice is hereby served that the annual general meeting of Nordic Nanovector ASA, (the "**Company**") will be held on 28 April 2022 at 14:00 hours (CEST) at Advokatfirmaet Selmer, Tjuvholmen Allé 1, 0252 Oslo.

The general meeting will be opened by the chairman of the board of directors, Jan Hendrik Egberts, or a person appointed by the board of directors cf. Section 5-12 of the Norwegian Public Limited Liability Companies Act.

The following matters are on the agenda:

- | | |
|--|--|
| 1. Election of a chairperson for the meeting and a person to co-sign the minutes | 7. Determination of remuneration for the members of the Nomination Committee |
| 2. Approval of the notice and the agenda | 8. Resolution to issue warrants in connection with the PSU-program |
| 3. Approval of the annual accounts and the directors' annual report for Nordic Nanovector ASA and the group for the financial year 2021, including allocation of the result of the year, as well as consideration of the statement on corporate governance | 9. Authorisation to the Board to increase the share capital in connection with the exercise of RSUs |
| 4. Advisory vote on the Company's remuneration report for 2021 | 10. Authorisation to the Board to increase the share capital by up to 20% for other specified purposes |
| 5. Approval of the auditor's fee | 11. Election of Board Members |
| 6. Determination of remuneration for the members of the Board (including approval of the issuance of RSUs to the members of the Board) | 12. Election of members of the Nomination Committee |

Nordic Nanovector ASA is a public limited company subject to the rules of the Norwegian Public Limited Companies Act. As of the date of this notice, the Company has issued 116,035,298 shares, each of which represents one vote. The shares have equal rights also in all other respects.

Pursuant to Section 7 of the Company's Articles of Association, the Board has decided that shareholders wishing to attend the General Meeting (in person or by proxy) must give notice to the Company of this by sending the enclosed registration form (which is also available on the Company's website as set out below) to the Company, c/o the Company's security account manager, Nordea Bank Abp, Norwegian branch, Issuer Services, by letter to the following address: Nordea Bank Abp, Norwegian branch, Issuer Services, P.O. Box 1166 Sentrum, N-0107 Oslo, Norway, or e-mail to: nis@nordea.com. The notice of attendance must have been received no later than 26 April 2022 at 16:00 hours (CEST). Any failure to register within the deadline may result in the shareholder being denied access to the general meeting.

Shareholders may participate at the general meeting electronically. The Company still encourages shareholders to vote in advance or submit proxies with voting instructions in advance of the general meeting, as further described below. Shareholders who wish to participate electronically must notify the Company of this by e-mail to e-mail: legal@nordicnanovector.com, no later than 26 April 2022 at 16:00 hours (CEST). Practical information for such participation will be provided to those it concerns before the general meeting.

Shareholders that are prevented from attending may be represented by proxy. The proxy form, including detailed instructions for the use of the form, is enclosed to this notice and is available on the Company's website as set out below. If desirable, proxy may be given to the Chairman of the Board, Jan Hendrik Egberts. Completed proxy forms may either be submitted at the general meeting or sent to the Company's security account manager, Nordea Bank Abp, Norwegian branch, Issuer Services within 26 April 2022 at 16:00 hours (CEST) by letter to the following address: Nordea Bank Abp, Norwegian branch, Issuer Services, P.O. Box 1166 Sentrum, N-0107 Oslo, Norway, or e-mail: nis@nordea.com.

A shareholder who cannot attend the general meeting may in advance cast a vote on each agenda item via www.nordicnanovector.com and Euronext Securities Oslo (formerly VPS) ("**ESO**") Investor Services. The deadline for prior voting is 26 April 2022 at 16:00 hours (CEST). Until the deadline, votes already cast may be changed or withdrawn. Votes already cast prior to the general meeting will be considered withdrawn if the shareholder attends the general meeting in person or by proxy.

If shares are registered on a nominee account in the ESO register, cf. Section 4-10 of the Norwegian Public Limited Companies Act, and the beneficial shareholder wants to vote for its shares, the beneficial shareholder must re-register the shares in a separate ESO account in its own name prior to the General Meeting, or prove that the transfer to such account has been reported to the ESO prior to the General Meeting.

A shareholder may make proposals for resolutions with respect to matters on the agenda and may require that members of the Board and the CEO at the general meeting provide available information about matters which may affect the assessment of (i) the approval of the annual accounts and the Board's annual report, (ii) matters that are presented to the shareholders for decision and (iii) the Company's financial situation, including operations in other companies the Company participates in, and other matters to be discussed at the general meeting, unless the requested information cannot be disclosed without causing disproportionate damage to the Company.

This notice, other documents regarding matters to be discussed in the general meeting, including the documents to which this notice refers, as well as the Company's Articles of

Association, are available on the Company's website www.nordicnanovector.com. Shareholders may contact the Company by mail, e-mail or telephone in order to request the documents in question on paper. Address: Nordic Nanovector ASA, Kjelsåsveien 168B, N-0884 Oslo, Norway, e-mail: ir@nordicnanovector.com, telephone: +47 22 18 33 01.

The following documents will be made available at www.nordicnanovector.com:

- This notice and the enclosed form for notice of attendance/proxy
- The Board of Directors' proposed resolutions for the items listed on the agenda
- The recommendation of the Nomination Committee
- The annual accounts and annual report for the financial year 2021
- The Board of Directors' Corporate Governance Report for 2021
- The remuneration report for 2021

Oslo, 6 April 2022

On behalf of the Board of Directors of Nordic Nanovector ASA

Jan Hendrik Egberts
Chairman

Appendices:

- Form of registration
- Form of proxy

**NORDIC NANOVECTOR ASA
NOTICE OF ATTENDANCE
ANNUAL GENERAL MEETING 28 APRIL 2022**

Shareholders who wish to attend the Annual General Meeting to be held on 28 April 2022 are requested to fill in and return this notice of attendance to: Nordea Bank Abp, Norwegian branch, Issuer Services, P.O. Box 1166 Sentrum, N-0107 Oslo, Norway or E-mail: nis@nordea.com.

Attendance may also be registered electronically through ESO Investor Services.

Notification of attendance must be received by Nordea no later than 26 April 2022 at 16:00 hours (CEST).

The undersigned wishes to attend the Annual General Meeting on 26 April 2022 at 14:00 hours (CEST).

Name of shareholder

Representative for a shareholder
(if a corporation)

Date

Place

Shareholder's signature

If the shareholder is a company, please attach documentation in the form of certificate of registration, or separate power of attorney.

**NORDIC NANOVECTOR ASA
POWER OF ATTORNEY
ANNUAL GENERAL MEETING 28 APRIL 2022**

Shareholders who do not return the form "NOTICE OF ATTENDANCE – ANNUAL GENERAL MEETING 28 April 2022" (see the previous page), and therefore wishes to authorise another person to act on his or her behalf at the Annual General Meeting on 28 April 2022 must complete this power of attorney form and return it to: Nordea Bank Abp, Norwegian branch, Issuer Services, P.O. Box 1166 Sentrum, N-0107 Oslo, Norway, or E-mail: nis@nordea.com.

Powers of attorney may also be registered electronically through ESO Investor Services.

The power of attorney must be received by Nordea no later than 26 April 2022 at 16:00 hours (CEST).

The undersigned hereby grants (please tick):

☐

The Chairman of the Board, Jan Hendrik Egberts, or the person he appoints, or

☐

Name of attorney (*please use capital letters*)

power of attorney to attend and vote for my/our shares at the Annual General Meeting of Nordic Nanovector ASA to be held on 28 April 2022 at 14.00 hours (CEST). If the power of attorney form is submitted without stating the name of the attorney, the power of attorney will be deemed to have been given to the Chairman of the Board Jan Hendrik Egberts or the person he appoints. Neither the Company nor the Chairman of the Board (and whoever the Chairman of the Board appoints) can be held responsible for any loss resulting from the proxy form not being received by the proxy in time. The Company and the Chairman of the board (and whoever the Chairman of the board appoints) are not responsible for ensuring that votes will be cast in accordance with the proxy form and have no responsibility in connection with cast of votes pursuant to the proxy form.

The votes shall be cast in accordance with the instructions below. Please note that **if the alternatives below are not ticked off, this will be deemed to be an instruction to vote "in favour" of the proposals in the notice**, provided, however, that the attorney determines the voting to the extent proposals are put forward in addition to, instead of, or as adjustments to the proposals in the notice. If the voting instruction is unclear, the holder will exercise his power of attorney based on a for the holder reasonable assessment of the instruction. If such assessment is not possible, the holder may abstain from voting.

Item:	In favour	Against	Abstain	At the attorney's discretion
1. Election of the chairman for the meeting				
1. Election of one person to co-sign the minutes				
2. Approval of the notice and the agenda of the meeting				
3. Approval of the annual accounts and the directors report				
4. Advisory vote on the Company's remuneration report for 2021				
5. Approval of the auditor's fee				
6. Determination of remuneration to the members of the Board (including approval of the issuance of restricted stock units (RSUs) to the members of the Board), in accordance with the Nomination Committee's proposal				
7. Determination of remuneration to the members of the Nomination Committee, in accordance with the Nomination Committee's proposal				
8. Resolution to issue warrants for the PSU-program				
9. Authorisation to the Board to increase the share capital in connection with exercise of RSUs				
10. Authorisation to the Board to increase the share capital by 20% for other specified purposes				
11. Re-election of Jan Hendrik Egberts as member and chairman of the board				
11. Re-election of Jean-Pierre Bizzari as a board member				



11. Re-election of Joanna Horobin as a board member				
11. Re-election of Karin Meyer as board member				
11. Re-election of Solveig Hellebust as board member				
11. Election of Thomas Ramdahl as board member				
12. Re-election of Johan Christenson as member and chairman of the Nomination Committee				
12. Re-election of Pål Erik Robinson as a member of the Nomination Committee				
12. Election of Hans-Peter Bøhn as a member of the Nomination Committee				

Name of shareholder

Representative for a shareholder
(if a corporation)

Date

Place

Shareholder's signature

If the shareholder is a company, please attach documentation in the form of certificate of registration, or separate power of attorney, if applicable, to this power of attorney.



**PROTOKOLL FRA ORDINÆR
GENERALFORSAMLING**

I

NORDIC NANOVECTOR ASA

ORG. NR. 994 297 422

Det ble avholdt ordinær generalforsamling i Nordic Nanovector ASA ("**Selskapet**") den 28. april 2022, kl. 14:00 hos advokatfirmaet Selmer, Tjuvholmen Allé 1, 0252 Oslo.

Generalforsamlingen ble åpnet av styrets leder, Jan Hendrik Egberts, som opptok en fortegnelse over de møtende aksjonærer.

22 138 360 av totalt 116 035 298 aksjer og stemmer i Selskapet var representert, tilsvarende 19,08% av samtlige aksjer. En oversikt over de møtende aksjonærene er inntatt som Vedlegg 1 til protokollen.

Stemmegivning for de enkelte saker på dagsordenen er vedlagt protokollen som Vedlegg 2.

Generalforsamlingen gikk så over til å behandle følgende dagsorden:

Dagsorden:

1. Valg av møteleder og en person til å medundertegne protokollen

Jan Hendrik Egberts ble valgt som møteleder og Jon Fredrik Johansen ble valgt til å medundertegne protokollen.

2. Godkjenning av innkallingen og dagsorden

Det ble opplyst at innkallingen var blitt tilsendt samtlige aksjonærer med kjent oppholdssted den 6. april 2022.

Innkallingen og dagsorden ble godkjent.

(OFFICE TRANSLATION)

**MINUTES OF ANNUAL GENERAL
MEETING**

OF

NORDIC NANOVECTOR ASA

REG. NO. 994 297 422

The annual general meeting of Nordic Nanovector ASA, (the "**Company**") was held on 28 April 2022, at 14:00 hours CEST at Advokatfirmaet Selmer, Tjuvholmen Allé 1, 0252 Oslo.

The general meeting was opened by the chairman of the board of directors (the "**Board**"), Jan Hendrik Egberts, who registered the attending shareholders.

22,138,360 of a total of 116,035,298 shares were represented at the general meeting, equal to 19.08% of the total number of shares. An overview over the attending shareholders is attached to the minutes as Appendix 1.

The voting for each of the items on the agenda is attached to the minutes as Appendix 2.

The meeting discussed the following matters:

Agenda:

1. Election of a chairperson for the meeting and a person to co-sign the minutes

Jan Hendrik Egberts was elected as chairperson and Jon Fredrik Johansen was elected to co-sign the minutes.

2. Approval of the notice and the agenda

It was informed that the notice of the general meeting had been sent to all shareholders with a known address on 6 April 2022.

The notice and the agenda were approved.



Møtelederen erklærte generalforsamlingen for lovlig satt.

3. Godkjenning av årsregnskapet og styrets årsberetning for Nordic Nanovector ASA og konsernet for regnskapsåret 2021, herunder disponeringen av årets resultat, samt behandling av redegjørelse for foretaksstyring

Møteleder viste til årsregnskapet og årsberetningen for morselskap og konsern samt revisors beretning som alle er inntatt i Selskapets årsrapport for 2021 som er gjort tilgjengelig på Selskapets internettsider, jf. vedtektenes § 7 første avsnitt.

Årsregnskapet og årsberetningen for regnskapsåret 2021 ble godkjent.

4. Rådgivende avstemning over Selskapets lederlønnssrapport for 2021

Møteleder viste til styrets rapport om godtgjørelse til Selskapets ledende personer («**Lederlønnssrapporten**»), som er gjennomgått av Selskapets revisor, jf. allmennaksjeloven § 6-16b, og som er gjort tilgjengelig på Selskapets internettsider.

Generalforsamlingen behandlet Lederlønnssrapporten i henhold til allmennaksjeloven § 5-6 (4) ved rådgivende avstemning. Resultatet av avstemningen er inntatt som Vedlegg 2 til protokollen.

5. Godkjenning av revisors godtgjørelse

Det ble vedtatt å godkjenne revisjons-godtgjørelsen til Selskapets revisor Ernst & Young AS for regnskapsåret 2021 på NOK 330 000.

6. Fastsettelse av godtgjørelse til styrets medlemmer (herunder godkjenning av utstedelse av RSUer til styrets medlemmer)

The chairperson declared the general meeting as lawfully convened.

3. Approval of the annual accounts and the board of directors' report for Nordic Nanovector ASA and the group for the financial year 2021, including allocation of the result of the year, as well as consideration of the statement on corporate governance

The chairperson referred to the annual accounts and the board of directors' report for the parent company and the group, together with the auditor's report, which are all included in the Company's annual report for 2021, which is available on the Company's website, cf. the first paragraph of Section 7 of the Articles of Association.

The annual accounts and the board of directors' report for the financial year 2021 were approved.

4. Advisory vote on the Company's remuneration report for 2021

The chairperson referred to the Board's report on the remuneration of the Company's senior executives (the "**Remuneration Report**"), which has been reviewed by the Company's auditor, cf. the Norwegian Public Limited Companies Act, section 6-16b, and which is made available on the Company's website.

The general meeting dealt with the Remuneration Report in accordance with Section 5-6 (4) of the Norwegian Public Limited Liability Companies Act by way of giving an advisory vote. The result from the vote is included in Appendix 2 to the minutes.

5. Approval of the auditor's fee

It was resolved to approve the auditor's fee to the Company's auditor Ernst & Young AS for the financial year 2021 of NOK 330,000.

6. Determination of remuneration for the members of the Board (including approval of the issuance of RSUs to the members of the Board)



Det ble redegjort for valgkomitéens forslag til fastsettelse av godtgjørelse til styrets medlemmer, herunder utstedelse av RSUer til styrets medlemmer.

Valgkomitéens forslag ble godkjent.

7. Fastsettelse av godtgjørelse til valgkomitéens medlemmer

Det ble redegjort for valgkomitéens forslag til fastsettelse av godtgjørelse til valgkomitéens medlemmer.

Valgkomitéens forslag om godtgjørelse til valgkomitéens medlemmer ble godkjent.

8. Vedtak om å utstede frittstående tegningsretter i forbindelse med PSU-program

Møteleder redegjorde for behovet for å sikre oppfyllelse av Selskapets forpliktelser under PSU-programmet ved utstedelse av frittstående tegningsretter til Selskapets ledende ansatte og andre ansatte som tildeles PSUer.

Generalforsamlingen fattet deretter følgende vedtak:

1. Det utstedes minimum 10 000 og maksimum 1 500 000 frittstående tegningsretter.
2. Hver tegningsrett gir, på de vilkår som er inntatt nedenfor, rett til utstedelse av én aksje pålydende NOK 0,20 i selskapet.
3. De frittstående tegningsrettene kan tegnes av ansatte som er tildelt PSUer i henhold til Selskapets langsiktige aksjebaserte incentivprogram etter styrets beslutning i perioden fra den ordinære generalforsamlingen i 2022 frem til den ordinære generalforsamlingen i 2023 ("**Perioden**"). De ansatte vil ha rett til å tegne én frittstående tegningsrett for hver PSU de er tildelt i Perioden. Eksisterende aksjeeiere skal ikke ha fortrinnsrett til tegning av de frittstående tegningsrettene etter

The Nomination Committee's proposal regarding determination of remuneration for the members of the Board, including approval of the issuance of RSUs to the members of the Board, was accounted for.

The Nomination Committee's proposal was approved.

7. Determination of remuneration for the members of the Nomination Committee

The Nomination Committee's proposal regarding determination of remuneration for the members of the Nomination Committee was accounted for.

The Nomination Committee's proposal on remuneration of the members of the Nomination Committee was approved.

8. Resolution to issue warrants in connection with the PSU-program

The chairperson accounted for the need to secure compliance with the Company's obligations under the PSU-program by issuance of warrants to the Company's senior management and other employee who are allocated PSUs.

The general meeting passed the following resolution:

1. The Company shall issue a minimum of 10,000 and a maximum of 1,500,000 warrants.
2. Each independent subscription right shall, subject to the terms set out below, give the right to subscribe for one new share in the Company with nominal value NOK 0.20.
3. The warrants can be subscribed by employees who have been awarded PSUs under the Company's long term equity incentive plan upon the decision by the Board during the period from the annual general meeting in 2022 to the annual general meeting in 2023 (the "**Period**"). The employees will have a right to subscribe for one warrant for each allocated PSU during the Period. Existing shareholders shall not have preferred rights to subscribe for the warrants pursuant to the Norwegian Public Limited Companies



reglene i allmennaksjeloven § 11-13, jf. §§ 10-4 og 10-5.

4. Tegningsperioden for de frittstående tegningsrettene løper fra 1. februar 2023 og frem til 30. mars 2023. De frittstående tegningsrettene skal tegnes i et eget tegnings skjema.
5. Det skal ikke betales vederlag for utstedelsen av de frittstående tegningsrettene.
6. Tegningskursen for aksjer utstedt med grunnlag i de frittstående tegningsrettene skal være lik pålydende, NOK 0,20 per aksje.
7. Innehaver kan bare benytte de frittstående tegningsrettene til å tegne aksjer som innehaver har rett til å tegne i henhold til PSUer tildelt i Perioden, likevel slik at ingen frittstående tegningsrett kan innløses i aksjer senere enn fem år etter datoen for denne generalforsamlingen.
8. Innehaveren av frittstående tegningsretter skal ikke ha rettigheter som aksjeeier ved beslutning om forhøyelse eller nedsetting av aksjekapitalen, ved beslutning om utstedelse av tegningsretter, eller ved oppløsning, fusjon, fisjon eller omdanning, med unntak for aksjer som er utstedt og fullt innbetalt av innehaveren av tegningsretten. Ved endring i Selskapets aksjekapital, som aksjesplitt, spleis eller andre kapitalhandlinger som fremgår av PSU-avtalene, skal vilkårene for tegningsrettene (tegningskurs og/eller antall aksjer som utstedes ved utøvelse) justeres slik det fremgår av PSU-avtalene.
9. Aksjer utstedt på grunnlag av frittstående tegningsretter gir rett til utbytte som er vedtatt etter den dato da aksjen ble utstedt
10. Som del av det langsiktige aksjebaserte incentivprogrammet kan de frittstående tegningsrettene ikke overdras. Utestående frittstående tegningsretter bortfaller dersom vilkårene for å utøve dem ikke oppfylles.

Act section 11-13, cf. sections 10-4 and 10-5.

4. The subscription period for the warrants shall be from 1 February 2023 and until 30 March 2023. The warrants shall be subscribed for on a separate subscription form.
5. No compensation shall be paid for the issuance of the warrants.
6. The subscription price to be paid for the shares issued on the basis of the warrants shall be the par value of the shares, NOK 0.20 per share.
7. The holder can only exercise the warrants to subscribe for shares the holder is entitled to subscribe for pursuant to PSUs allocated during the Period, but so that no warrants can be exchanged for shares later than five years following the date of this general meeting.
8. The holder of the warrants shall not have rights as a shareholder with regard to capital increases, capital reductions, or a resolution to issue subscription rights, dissolution, merger, demerger or reorganization, except with respect to shares that have been issued to and paid for by the warrant holder. Upon changes in the Company's share capital, such as share splits, reverse splits and other capital actions as provided for in the PSU-agreements, the subscription rights terms (subscription price and/or number of shares to be issued upon exercise) shall be adjusted as set out in PSU-agreements.
9. Shares issued on the basis of the warrants shall give right to dividends declared following the date the shares are issued.
10. As part of the long term equity incentive plan, the warrants cannot be transferred. The outstanding warrants will lapse if the conditions for exercising them are not met.



9. Fullmakt til styret til å forhøye aksjekapitalen i tilknytning til utøvelse av RSUer

Møteleder redegjorde for forslaget. I samsvar med styrets forslag traff generalforsamlingen følgende vedtak:

1. I henhold til allmennaksjeloven § 10-14 gis styret fullmakt til, i en eller flere omganger, å forhøye Selskapets aksjekapital med inntil NOK 50 000.
2. Fullmakten kan bare benyttes til utstedelse av aksjer til Selskapets styremedlemmer ved utøvelse av tildelte RSUer.
3. Fullmakten gjelder i to år fra datoen for dette vedtaket.
4. Aksjonærenes fortrinnsrett til de nye aksjene etter allmennaksjeloven § 10-4 kan fravikes.
5. Fullmakten omfatter ikke kapitalforhøyelse mot innskudd i andre eiendeler enn penger mv, jf. allmennaksjeloven § 10-2.
6. Fullmakten omfatter ikke kapitalforhøyelse ved fusjon etter allmennaksjeloven § 13-5.
7. Denne fullmakten erstatter fullmakten som ble gitt for det samme formålet i den ordinære generalforsamlingen i 2021, fra det tidspunkt denne nye fullmakten er registrert i Foretaksregisteret

10. Fullmakt til styret til å forhøye aksjekapitalen med opp til 20% for andre angitte formål

Møteleder redegjorde for styrets forslag.

1. I henhold til allmennaksjeloven § 10-14 gis styret fullmakt til å forhøye

9. Authorisation to the Board to increase the share capital in connection with the exercise of RSUs

The chairperson accounted for the proposal. In accordance with the Board's proposal, the general meeting passed the following resolution:

1. Pursuant to Section 10-14 of the Norwegian Public Limited Companies Act, the Board is authorised to, in one or more occurrences, increase the Company's share capital by up to NOK 50,000.
2. The authorisation may only be used to issue shares to members of the Company's Board upon exercise of awarded RSUs.
3. The authorisation is valid for a period of two years from the date of this resolution.
4. The shareholders' preferential right to the new shares pursuant to Section 10-4 of the Norwegian Public Limited Companies Act may be deviated from.
5. The authorisation does not comprise share capital increases against contribution in kind, cf. Section 10-2 of the Norwegian Public Limited Companies Act.
6. The authorisation does not comprise share capital increase in connection with mergers pursuant to Section 13-5 of the Norwegian Public Limited Companies Act.
7. This authorisation replaces the authorisation granted at the annual general meeting in 2021 for the same purpose, from the date this new authorisation is registered in the Norwegian Register of Business Enterprises.

10. Authorisation to the Board to increase the share capital by up to 20% for other specified purposes

The chairperson of the Meeting accounted for the proposals.

1. Pursuant to Section 10-14 of the Norwegian Public Limited Companies



Selskapets aksjekapital, i en eller flere omganger, med inntil NOK 4 641 412.

2. Fullmakten kan benyttes til å styrke Selskapets egenkapital, generelle forretningsmessige formål, herunder men ikke begrenset til finansiering av oppkjøp av andre selskaper, virksomheter eller eiendeler herunder for utstedelse av vederlagsaksjer i forbindelse med overnevnte transaksjoner.
3. Fullmakten gjelder frem til Selskapets ordinære generalforsamling i 2023, likevel ikke lenger enn til 30. juni 2023.
4. Aksjonærenes fortrinnsrett til de nye aksjene etter allmennaksjeloven § 10-4 kan fravikes.
5. Fullmakten omfatter kapitalforhøyelse mot innskudd i penger og/eller i andre eiendeler enn penger og/eller rett til å pådra Selskapet særlige forpliktelser mv, jf. allmennaksjeloven § 10-2. Fullmakten omfatter beslutning om fusjon i henhold til allmennaksjeloven § 13-5.

11. Valg av styremedlemmer

Det ble redegjort for valgkomitéens innstilling om valg av styremedlemmer.

Følgende ble, i overenstemmelse med valgkomitéens innstilling, valgt som styremedlemmer for perioden frem til ordinær generalforsamling i 2023:

Jan Hendrik Egberts (styreleder)

Jean-Pierre Bizzari

Joanna Horobin

Karin Meyer

Solveig Hellebust

Thomas Ramdahl

Act, the Board is granted an authorisation to increase the Company's share capital, in one or more occurrences, by up to NOK 4,641,412.

2. The authorisation may be used to strengthen the Company's equity, for general corporate purposes, including but not limited to financing of acquisitions of other companies, businesses or assets, including issuance of consideration shares in connection with the above mentioned transactions.
3. The authorisation is valid until the Company's annual general meeting in 2023, but no longer than 30 June 2023.
4. The shareholders' preferential right to the new shares pursuant to Section 10-4 of the Norwegian Public Limited Companies Act may be deviated from.
5. The authorisation comprises share capital increases against contribution in cash and/or in kind and/or the right to impose special obligations on the Company etc, cf. Section 10-2 of the Norwegian Public Limited Companies Act. The authorisation covers resolutions on mergers as provided in section 13-5 of the Norwegian Public Limited Companies Act.

11. Election of Board members

The Nomination Committee's proposal for election of board members was accounted for.

The following were, in accordance with the Nomination Committee's proposal, elected as board members for the period until the 2023 annual general meeting:

Jan Hendrik Egberts (styreleder)

Jean-Pierre Bizzari

Joanna Horobin

Karin Meyer

Solveig Hellebust

Thomas Ramdahl



12. Valg av medlemmer til valgkomiteen

Det ble redegjort for valgkomitéens innstilling om valg av medlemmer til valgkomitéen.

I overensstemmelse med valgkomitéens innstilling ble følgende valgt som medlemmer av valgkomitéen for en periode frem til ordinær generalforsamling i 2023.

Johan Christenson (leder)

Pål Erik Robinson

Hans-Peter Bøhn

Det var ikke flere saker på dagsorden. Generalforsamlingen ble deretter hevet og protokollen undertegnet.

12. Election of members to the Nomination Committee

The Nomination Committee's proposal for election of members to the Nomination Committee was accounted for.

In accordance with the Nomination Committee's proposal, the following were elected as members of the Nomination Committee for a period until the annual general meeting in 2023:

Johan Christenson (chair)

Pål Erik Robinson

Hans-Peter Bøhn

There were no further matters to be resolved. The meeting was adjourned and the minutes were signed.

In case of any discrepancies between the Norwegian text and the English translation, the Norwegian text shall prevail.

Oslo,

28. april / 28 April 2022

Jan Hendrik Egberts

Vedlegg:

- | | |
|---|---|
| 1 | Oversikt over antall aksjer og stemmer representert |
| 2 | Avstemmingsresultater |

Jon Fredrik Johansen

Appendices:

- | | |
|---|--|
| 1 | Overview of the number of shares and votes represented |
| 2 | Voting results |

Attendance List Attendance NORDIC NANOVECTOR ASA 28/04/2022

Ref no	First Name	Company/Last name	Repr. by	Participant	Share	Own	Proxy	Total	% sc	% represented	% registered
					Ordinær	11,308,098	0	11,308,098	9.75 %	51.08 %	50.90 %
18		Styrets leder, Jan Hendrik Egberts		Proxy Solicitor	Ordinær	0	269,769	10,426,276	8.99 %	47.10 %	46.93 %
463		OCOBIA M AS	Gustav Martinsen	Share Holder	Ordinær	236,000	0	236,000	0.20 %	1.07 %	1.06 %
1073		CORUNDUM AS	Lars-Petter Rinnan	Share Holder	Ordinær	120,000	0	120,000	0.10 %	0.54 %	0.54 %
5843	LARS OLAV	OTTESTAD		Share Holder	Ordinær	29,000	0	29,000	0.03 %	0.13 %	0.13 %
8862		KLEIN AS	.	Share Holder	Ordinær	18,786	0	18,786	0.02 %	0.09 %	0.09 %
83915	TORIL	RANGNES		Share Holder	Ordinær	200	0	200	0.00 %	0.00 %	0.00 %

Protocol for general meeting NORDIC NANOVECTOR ASA

ISIN: NO0010597883 NORDIC NANOVECTOR ASA
 General meeting date: 28/04/2022 14.00
 Today: 28.04.2022

Shares class	FOR	Against	Poll in	Abstain	Poll not registered	Represented shares with voting rights
Agenda item 1A Election of the chairman for the meeting						
Ordinær	22,118,360	0	22,118,360	20,000	0	22,138,360
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	99.91 %	0.00 %	99.91 %	0.09 %	0.00 %	
total sc in %	19.06 %	0.00 %	19.06 %	0.02 %	0.00 %	
Total	22,118,360	0	22,118,360	20,000	0	22,138,360
Agenda item 1B Election of one person to co-sign the minutes						
Ordinær	22,118,360	0	22,118,360	20,000	0	22,138,360
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	99.91 %	0.00 %	99.91 %	0.09 %	0.00 %	
total sc in %	19.06 %	0.00 %	19.06 %	0.02 %	0.00 %	
Total	22,118,360	0	22,118,360	20,000	0	22,138,360
Agenda item 2 Approval of the notice and the agenda of the meeting						
Ordinær	21,877,081	0	21,877,081	261,279	0	22,138,360
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	98.82 %	0.00 %	98.82 %	1.18 %	0.00 %	
total sc in %	18.85 %	0.00 %	18.85 %	0.23 %	0.00 %	
Total	21,877,081	0	21,877,081	261,279	0	22,138,360
Agenda item 3 Approval of the annual accounts and the directors report						
Ordinær	21,877,081	241,279	22,118,360	20,000	0	22,138,360
votes cast in %	98.91 %	1.09 %		0.00 %		
representation of sc in %	98.82 %	1.09 %	99.91 %	0.09 %	0.00 %	
total sc in %	18.85 %	0.21 %	19.06 %	0.02 %	0.00 %	
Total	21,877,081	241,279	22,118,360	20,000	0	22,138,360
Agenda item 4 Advisory vote on the Company's remuneration report for 2021						
Ordinær	21,871,580	241,370	22,112,950	25,410	0	22,138,360
votes cast in %	98.91 %	1.09 %		0.00 %		
representation of sc in %	98.80 %	1.09 %	99.89 %	0.12 %	0.00 %	
total sc in %	18.85 %	0.21 %	19.06 %	0.02 %	0.00 %	
Total	21,871,580	241,370	22,112,950	25,410	0	22,138,360
Agenda item 5 Approval of the auditor's fee						
Ordinær	22,118,269	91	22,118,360	20,000	0	22,138,360
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	99.91 %	0.00 %	99.91 %	0.09 %	0.00 %	
total sc in %	19.06 %	0.00 %	19.06 %	0.02 %	0.00 %	
Total	22,118,269	91	22,118,360	20,000	0	22,138,360
Agenda item 6 Determination of remuneration to the members of the Board (including approval of the Issuance of restricted stock units (RSUs) to the member						
Ordinær	21,748,490	386,370	22,134,860	3,500	0	22,138,360
votes cast in %	98.25 %	1.75 %		0.00 %		
representation of sc in %	98.24 %	1.75 %	99.98 %	0.02 %	0.00 %	
total sc in %	18.74 %	0.33 %	19.08 %	0.00 %	0.00 %	
Total	21,748,490	386,370	22,134,860	3,500	0	22,138,360
Agenda item 7 Determination of remuneration to the members of the Nomination Committee, in accordance with the Nomination Committee's proposal						
Ordinær	21,873,490	261,370	22,134,860	3,500	0	22,138,360
votes cast in %	98.82 %	1.18 %		0.00 %		
representation of sc in %	98.80 %	1.18 %	99.98 %	0.02 %	0.00 %	
total sc in %	18.85 %	0.23 %	19.08 %	0.00 %	0.00 %	
Total	21,873,490	261,370	22,134,860	3,500	0	22,138,360
Agenda item 8 Resolution to issue warrants for the PSU-program						
Ordinær	21,576,741	561,619	22,138,360	0	0	22,138,360
votes cast in %	97.46 %	2.54 %		0.00 %		
representation of sc in %	97.46 %	2.54 %	100.00 %	0.00 %	0.00 %	
total sc in %	18.60 %	0.48 %	19.08 %	0.00 %	0.00 %	
Total	21,576,741	561,619	22,138,360	0	0	22,138,360
Agenda item 9 Authorisation to the Board to increase the share capital in connection with exercise of RSUs						

Shares class	FOR	Against	Poll in	Abstain	Poll not registered	Represented shares with voting rights
Ordinær	21,582,060	556,300	22,138,360	0	0	22,138,360
votes cast in %	97.49 %	2.51 %		0.00 %		
representation of sc in %	97.49 %	2.51 %	100.00 %	0.00 %	0.00 %	
total sc in %	18.60 %	0.48 %	19.08 %	0.00 %	0.00 %	
Total	21,582,060	556,300	22,138,360	0	0	22,138,360
Agenda item 10 Authorisation to the Board to increase the share capital by 20% for other specified purposes						
Ordinær	21,711,185	426,943	22,138,128	232	0	22,138,360
votes cast in %	98.07 %	1.93 %		0.00 %		
representation of sc in %	98.07 %	1.93 %	100.00 %	0.00 %	0.00 %	
total sc in %	18.71 %	0.37 %	19.08 %	0.00 %	0.00 %	
Total	21,711,185	426,943	22,138,128	232	0	22,138,360
Agenda item 11 Election of Board Members						
Ordinær	21,871,580	246,780	22,118,360	20,000	0	22,138,360
votes cast in %	98.88 %	1.12 %		0.00 %		
representation of sc in %	98.80 %	1.12 %	99.91 %	0.09 %	0.00 %	
total sc in %	18.85 %	0.21 %	19.06 %	0.02 %	0.00 %	
Total	21,871,580	246,780	22,118,360	20,000	0	22,138,360
Agenda item 11.1 Re-election of Jan Hendrik Egberts as member and chairman of the board						
Ordinær	21,871,580	246,780	22,118,360	20,000	0	22,138,360
votes cast in %	98.88 %	1.12 %		0.00 %		
representation of sc in %	98.80 %	1.12 %	99.91 %	0.09 %	0.00 %	
total sc in %	18.85 %	0.21 %	19.06 %	0.02 %	0.00 %	
Total	21,871,580	246,780	22,118,360	20,000	0	22,138,360
Agenda item 11.2 Re-election of Jean-Pierre Bizzari as a board member						
Ordinær	21,871,580	246,780	22,118,360	20,000	0	22,138,360
votes cast in %	98.88 %	1.12 %		0.00 %		
representation of sc in %	98.80 %	1.12 %	99.91 %	0.09 %	0.00 %	
total sc in %	18.85 %	0.21 %	19.06 %	0.02 %	0.00 %	
Total	21,871,580	246,780	22,118,360	20,000	0	22,138,360
Agenda item 11.3 Re-election of Joanna Horobin as a board member						
Ordinær	21,871,580	246,780	22,118,360	20,000	0	22,138,360
votes cast in %	98.88 %	1.12 %		0.00 %		
representation of sc in %	98.80 %	1.12 %	99.91 %	0.09 %	0.00 %	
total sc in %	18.85 %	0.21 %	19.06 %	0.02 %	0.00 %	
Total	21,871,580	246,780	22,118,360	20,000	0	22,138,360
Agenda item 11.4 Re-election of Karin Meyer as board member						
Ordinær	21,871,580	246,780	22,118,360	20,000	0	22,138,360
votes cast in %	98.88 %	1.12 %		0.00 %		
representation of sc in %	98.80 %	1.12 %	99.91 %	0.09 %	0.00 %	
total sc in %	18.85 %	0.21 %	19.06 %	0.02 %	0.00 %	
Total	21,871,580	246,780	22,118,360	20,000	0	22,138,360
Agenda item 11.5 Re-election of Solveig Hellebust as board member						
Ordinær	21,871,580	246,780	22,118,360	20,000	0	22,138,360
votes cast in %	98.88 %	1.12 %		0.00 %		
representation of sc in %	98.80 %	1.12 %	99.91 %	0.09 %	0.00 %	
total sc in %	18.85 %	0.21 %	19.06 %	0.02 %	0.00 %	
Total	21,871,580	246,780	22,118,360	20,000	0	22,138,360
Agenda item 11.6 Election of Thomas Ramdahl as board member						
Ordinær	21,871,580	246,780	22,118,360	20,000	0	22,138,360
votes cast in %	98.88 %	1.12 %		0.00 %		
representation of sc in %	98.80 %	1.12 %	99.91 %	0.09 %	0.00 %	
total sc in %	18.85 %	0.21 %	19.06 %	0.02 %	0.00 %	
Total	21,871,580	246,780	22,118,360	20,000	0	22,138,360
Agenda item 12 Election of members of the Nomination Committee						
Ordinær	21,871,580	241,370	22,112,950	25,410	0	22,138,360
votes cast in %	98.91 %	1.09 %		0.00 %		
representation of sc in %	98.80 %	1.09 %	99.89 %	0.12 %	0.00 %	
total sc in %	18.85 %	0.21 %	19.06 %	0.02 %	0.00 %	
Total	21,871,580	241,370	22,112,950	25,410	0	22,138,360
Agenda item 12.1 Re-election of Johan Christenson as member and chairman of the Nomination Committee						
Ordinær	21,871,580	241,370	22,112,950	25,410	0	22,138,360
votes cast in %	98.91 %	1.09 %		0.00 %		
representation of sc in %	98.80 %	1.09 %	99.89 %	0.12 %	0.00 %	

Shares class	FOR	Against	Poll in	Abstain	Poll not registered	Represented shares with voting rights
total sc in %	18.85 %	0.21 %	19.06 %	0.02 %	0.00 %	
Total	21,871,580	241,370	22,112,950	25,410	0	22,138,360
Agenda Item 12.2 Re-election of Pål Erik Robinson as a member of the Nomination Committee						
Ordinær	21,871,580	241,370	22,112,950	25,410	0	22,138,360
votes cast in %	98.91 %	1.09 %		0.00 %		
representation of sc in %	98.80 %	1.09 %	99.89 %	0.12 %	0.00 %	
total sc in %	18.85 %	0.21 %	19.06 %	0.02 %	0.00 %	
Total	21,871,580	241,370	22,112,950	25,410	0	22,138,360
Agenda Item 12.3 Election of Hans-Peter Bøhn as a member of the Nomination Committee						
Ordinær	21,871,671	241,279	22,112,950	25,410	0	22,138,360
votes cast in %	98.91 %	1.09 %		0.00 %		
representation of sc in %	98.80 %	1.09 %	99.89 %	0.12 %	0.00 %	
total sc in %	18.85 %	0.21 %	19.06 %	0.02 %	0.00 %	
Total	21,871,671	241,279	22,112,950	25,410	0	22,138,360

Registrar for the company:

Signature company:

NORDEA BANK ABP, FILIAL NORGE

NORDIC NANOVECTOR ASA

Share information

Name	Total number of shares	Nominal value	Share capital	Voting rights
Ordinær	116,035,298	0.20	23,207,059.60	Yes
Sum:				

§ 5-17 Generally majority requirement

requires majority of the given votes

§ 5-18 Amendment to resolution

Requires two-thirds majority of the given votes

like the issued share capital represented/attended on the general meeting

Total Represented

ISIN: NO0010597883 NORDIC NANOVECTOR ASA
General meeting date: 28/04/2022 14.00
Today: 28.04.2022

Number of persons with voting rights represented/attended : 6

	Number of shares	% sc
Total shares	116,035,298	
- own shares of the company	0	
Total shares with voting rights	116,035,298	
Represented by own shares	403,986	0.35 %
Represented by advance vote	11,308,098	9.75 %
Sum own shares	11,712,084	10.09 %
Represented by proxy	269,769	0.23 %
Represented by voting instruction	10,156,507	8.75 %
Sum proxy shares	10,426,276	8.99 %
Total represented with voting rights	22,138,360	19.08 %
Total represented by share capital	22,138,360	19.08 %

Registrar for the company:

NORDEA BANK ABP, FILIAL NORGE

Signature company:

NORDIC NANOVECTOR ASA



RECOMMENDATION OF THE NOMINATION COMMITTEE

1. INTRODUCTION

The Nomination Committee of Nordic Nanovector ASA comprises of Johan Christenson (chairman), Egil Bodd and Pål Erik Robinson.

The Nomination Committee has since the previous annual general meeting, held 4 formal meetings, with numerous additional interactions via phone and e-mail. The Nomination Committee has discussed the work of the Board of directors (the "**Board**") and the Board's sub-committees with the Chairman of the Board. The Nomination Committee has interviewed Board members and certain members of the management team. The Nomination Committee has also received feedback from individual shareholders concerning the composition of the Board.

Prior to the annual general meeting to be held on 28 April 2022 (the "**2022 AGM**"), the Nomination Committee has discussed in detail the requirements the Board should fulfill in terms of competences, experience and background, taking into account, among other things, the Company's strategic development, governance and control as well as the size, breadth and diversity of competence, age, gender, background and experience. In addition, independency matters have been taken into account in the Nomination Committee's discussions, and an assessment has also been made of the capacity for each individual Board member to devote sufficient time and commitment to the work of the Board.

The term for all the current members of the Board and all the members of the Nomination Committee expires on the date of the 2022 AGM. Further, the remuneration for the Board and the members of the Nomination Committee has been resolved for the period until the 2022 AGM.

In accordance with the Articles of Association and the Instructions for the Nomination Committee adopted by the General Meeting held on 12 November 2014 and amended on the General Meeting held on 24 May 2017 (the "**Instructions**"), the Nomination Committee will in this recommendation present its proposals for members of the Board, members of the Nomination Committee, and remuneration for such members.

The Nomination Committee has, when preparing its proposals, taken into consideration the matters that are to be taken into consideration by the Nomination Committee pursuant to the Instructions, and such other matters which the Nomination Committee has deemed appropriate as further described above. The proposals have been unanimously resolved by the Nomination Committee.

2. NOMINATION OF BOARD OF DIRECTORS

The Board has seven shareholder-elected members and currently consists of the following members:

Name	Served since	Term expire
Jan Hendrik Egberts, Chairman	February 2019	2022 AGM
Per Samuelsson	November 2014	2022 AGM
Jean-Pierre Bizzari	May 2016	2022 AGM
Joanna Horobin	October 2016	2022 AGM
Rainer Boehm	May 2018	2022 AGM
Karin Meyer	June 2020	2022 AGM
Solveig Hellebust	April 2021	2022 AGM

Except for Per Samuelsson and Rainer Boehm, all of the Board members are up for election at the 2022 AGM. The Nomination Committee proposes that these Board members are re-elected for one year until the annual general meeting in 2022 (the "**2022 AGM**"). Per Samuelsson who has served as a Board member since November 2014 and Rainer Boehm who has served as a Board member since May 2018, have, due to increased workload, responsibilities and competing priorities, decided not to stand for re-election at the 2022 AGM.

Dr. Thomas Ramdahl has been nominated for election as a new board member at the 2022 AGM. Dr Ramdahl is a pharmaceutical executive with more than 20 years of clinical and development experience. In 2001, he became President and first CEO of Algeta ASA, a Norwegian biotech company that successfully developed and launched a radiopharmaceutical for prostate cancer.

During his time at Algeta, the company successfully completed Phase 1 and 2 clinical trials, as well as a pivotal Phase 3 multicentre, multi-country, double blinded clinical trial that led to FDA approval and marketing approval of Algeta's lead product, Xofigo®.

In addition to playing a key role in Algeta's 2007 IPO and in multiple fundraisings, he was instrumental in the acquisition of the company by Bayer AG for USD 2.9 billion in 2014. After the acquisition by Bayer, Dr Ramdahl held the position of Managing Director of Bayer in Norway, remaining in this role until October 2018.

Dr Ramdahl is currently Chairman at Precirix and a Board Director at Clarity Pharmaceuticals, both in the targeted radiopharmaceutical area, and Chairman at medical device company Appsens. He has authored more than 40 publications and is a co-inventor of several patents. He gained his PhD in environmental chemistry from the University of Oslo in 1984 and an MSc in organic chemistry from the Norwegian Institute of Technology in 1979. Dr. Ramdahl is a Norwegian citizen and resides in Norway.

The Nomination Committee has emphasized that the Board should be diverse in terms of background, competence and experience and it is the Nomination Committee's view that the proposed Board composition ensures these qualities.

If the 2022 AGM adopts the Nomination Committee's proposal, all the Board members will continue to serve to the 2023 AGM when their renewed term will expire.

Information regarding the current members of the Board is available at Nordic Nanovector's website: www.nordicnanovector.com.

All proposed Board members are independent of the Company's significant business relations and large shareholders (shareholders holding more than 5% of the shares in the Company). The proposed Board composition is compliant with the requirements for independence as set out in the Norwegian Code of Practice for Corporate Governance (NUES).

3. NOMINATION OF NOMINATION COMMITTEE

The Company's Nomination Committee currently consists of the following members:

Name	Served since	Term Expire
Johan Christenson, Chairman	November 2014	2022 AGM
Egil Bodd	May 2018	2022 AGM
Pål Erik Robinson	June 2020	2022 AGM

Except for Egil Bodd, all of the Nomination Committee members are up for election at the 2022 AGM. It is proposed that Hans-Peter Bøhn is elected as a new member of the Nomination Committee. The members are elected for a period of one year until the 2023 AGM.

Hans-Peter Bøhn is a Norwegian citizen with a medical degree. He started his pharmaceutical industry career as medical adviser in Nycomed Imaging. Over the ensuing 12 years he gained broad experience from management positions in the pharmaceutical industry within drug safety, international marketing and operations and clinical research as well as gaining a post-graduate Diploma of Pharmaceutical Medicine. After the years in the industry he joined Fondsfinans as a financial analyst covering the life science sector. From 2012 he has been manager of the non-profit "Svanhild og Arne Musts Fond for Medisinsk Forskning" as well as serving as an independent adviser to among others the Research Council of Norway, the Norwegian Cancer Society, Innovation Norway, Oslo Cancer Cluster as well as a number of biotech start-up companies. Hans-Peter serves as a Board member of PCI Biotech, SpinChip Diagnostics and Cura8 and joined the board of Zelluna in September 2018.

Information regarding the current members of the Nomination Committee is available at Nordic Nanovector's website: www.nordicnanovector.com.

4. REMUNERATION OF THE BOARD OF DIRECTORS

4.1 Remuneration to the Board of directors for the period from the 2022 AGM to the 2023 AGM

In order to attract eligible Board-members with relevant international experience, the Nomination Committee has previously, through an independent consultant, conducted a peer group analysis on board compensation. Based on this analysis and further considerations, the Nomination Committee, proposes that the remuneration to the Board of directors may be given, in full or in part, in the form of restricted share units (see section 4.2 below).

The Committee further proposes that the 2022 AGM resolves that the remuneration for the Chairman and the members of the Board for the period from the 2022 AGM to the 2023 AGM shall be:

Chairman	-	NOK 600,000
Directors	-	NOK 330,000

The Nomination Committee further proposes that members of Board Committees such as the Audit Committee, the Compensation Committee and the Clinical Strategy Committee

shall receive an additional remuneration of NOK 4,000 per committee meeting, but not less than NOK 20,000 for each committee member (NOK 8,000 per meeting and minimum NOK 40,000 to the chairpersons of each of the committees). In order to attract international board members, the Nomination Committee proposes to pay Board members EUR 100 per lost working hour when traveling to attend the Board meetings.

4.2 Restricted stock units to the Board members

The annual general meeting in May 2016 approved a program (the "**RSU Program**") pursuant to which the members of the Board may choose to receive their remuneration, or parts thereof, in the form of restricted stock units ("**RSUs**"). The RSU Program was renewed at the annual general meetings in 2017, 2018, 2019, 2020 and 2021. The Nomination Committee recommends that the RSU Program is continued and that the Board members shall have the right to receive their remuneration, or a part thereof, for the period from the 2022 AGM to the 2023 AGM in the form of RSUs. Each member of the Board will have three alternatives when the remuneration to the members of the Board is resolved by the 2022 AGM:

- a) Receive 100 % of the Board remuneration in the form of RSUs;
- b) Receive 1/3 of the Board remuneration in cash and 2/3 in the form of RSUs; or
- c) Receive 2/3 of the Board remuneration in cash and 1/3 in the form of RSUs;

For further information of the RSU Program, see page 89 in the company's annual report for 2021, which is available at Nordic Nanovector's website www.nordicnanovector.com.

5. REMUNERATION OF THE NOMINATION COMMITTEE

The Nomination Committee further proposes that the 2022 AGM resolves that the remuneration for the Chairman and the members of the Nomination Committee for the period from the 2022 AGM to the 2023 AGM shall be:

Chairman	-	NOK 45,000
Members	-	NOK 25,000

The Nomination Committee of Nordic Nanovector ASA

Johan Christenson
Chairman

Egil Bodd

Pål Erik Robinson